Dr. Wang on CAR T-Cell Therapy Resistance in MCL

Video

In Partnership With:

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma (MCL).

No single treatment can cure every patient, says Wang. Having treatment options in non-Hodgkin lymphoma is necessary, but resistance to these treatments continues to pose a challenge.

Therapies such as rituximab (Rituxan), ibrutinib (Imbruvica) and venetoclax (Venclexta) saw some success in this space, but long-term remission responses were not durable and patients eventually developed resistance to both modalities, Wang says.

The introduction of CAR T-cell therapy as a third treatment saw long-term remission in about 30% to 40% of patients, but a majority developed triple-resistance to chemotherapy, targeted therapy, and eventually, CAR T-cell therapy, he explains.

Personalized medicine may be the answer as it will expose driving resistance mechanisms in individual patients, Wang concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD